Shenyang Fuyang Pharmaceutical Technology Co., Ltd., established on 2016-11-17, Business scope includes drug research and development,retail;Drug R&D Technical Consulting,technology transfer,Technical Services;Business Management Consulting;Self-operated and agent import and export of various commodities and technologies,Except for the goods and technologies that the state restricts the company to operate or prohibits the import and export of.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments.)

Oncotherapy science (OTS) is“ to deliver cancer therapeutics and treatments with higher efficacy and fewer side effects to patients suffering from cancer as soon as possible, and to overcome the fight against cancer. Was established with the aim of OTS brought Professor Genomix (Science that handles genetic information systematically) as a pioneer in the medical field with Prof. Atsushi Nakamura (Director, Cancer Precision Medical Research Center, Institute of Cancer, Professor Emeritus, The University of Tokyo, Professor Emeritus of Chicago University) Joint research to identify target molecules suitable for cancer drug development based on comprehensive gene expression analysis, and promote research and development of small molecule drugs, cancer peptide vaccines and antibody drugs for those targets.

UbiVac is a clinical-stage biotechnology company engaged in the research and development of therapeutic vaccines to combat cancer. Founded in Portland, OR in 2005 as a spinout of the Robert W. Franz Cancer Research Center within the Earle A. Chiles Research Institute, at Providence Portland Medical Center, UbiVac continues to build upon the groundbreaking research being developed in the region.

University Health Network (UHN) is a healthcare and medical research organization in Toronto, Ontario, Canada. It is the largest such research organization in Canada and North America, ranking first in Canada for total research funding. It was named Canada's top research hospital by Research Infosource in 2015, 2016 and 2017. It was created in 1986 by the Government of Ontario through the merger of four major hospitals: Toronto General Hospital, Toronto Western Hospital, with the Princess Margaret Cancer Centre, and the Toronto Rehabilitation Institute merged in with The Toronto Hospital in 1999 and the name changed to the University Health Network. All four hospitals are affiliated with the Faculty of Medicine at the University of Toronto and serve as teaching hospitals for resident physicians, nurses, and other healthcare professions. UHN also operates The Michener Institute, an applied health sciences college that opened in 1958.

Heilongjiang Liansheng Biotechnology Co., Ltd., established on 2020-05-26, Business scope includes general items:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Research and development of bio-based materials technology;Medical Research and Experimental Development;New material technology research and development;Development of Human Gene Diagnosis and Therapy Technology;R&D and application of cell technology;Sales of Class I Medical Devices;Chemical product sales(No licensed chemical products);Instrument sales;Disinfectant sales(Free of Hazardous Chemicals);Sales of hygiene products and single-use medical products;Sales of labor protection products;Personal Hygiene Sales;Drug testing equipment sales;Experimental analysis instrument sales;Office Supplies Sales;internet data service;Artificial intelligence public data platform;Big data service;Data processing and storage support services.

Roche Glycart AG discovers and develops drugs. It is active in the research and development of new potent antibody-based products for the treatment of unmet clinical needs such as cancer. It uses its proprietary set of technologies to endow therapeutic antibodies. The company has developed glycoengineering technology (GlycoMAb) to boost a natural mechanism of action of therapeutic antibodies developed to mediate target cell killing. The company was founded in 2000 and is headquartered in Zurich, Switzerland.

Shanghai LIDE Biotech Co. Ltd. is a private company headquartered in Pudong, China, involved in commercial physical and biological research.

RemeGen, Ltd. ("RemeGen") is a biopharmaceutical company in China dedicated to fulfilling unmet medical needs for patients with life-threatening conditions. RemeGen's main focus is research and development, manufacturing and commercialization of novel biologics, most notably monoclonal antibodies (mAb) and antibody-drug conjugates (ADCs). Headquartered in Yantai, Shandong Province, China, RemeGen has labs/offices in Beijing and California.

Jiangsu Maijian Biotechnology Development Co., Ltd. is a private company headquartered in Wuxi, China. The firm wholesales cosmetics products.

Shandong Kaiti Biological Products Co., Ltd., established on 2018-10-22, Business scope includes biological products(In addition to vaccines)technology development,technology transfer,technical consulting,Technical Services;wholesale,retail:Biological product(In addition to vaccines),biological reagent;Import and export business(Excluding state trade management goods)and other legal,regulations,Items that are not prohibited by the State Council's decision and other regulations and do not require a business license.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Tianjin Medical University Cancer Institute and Hospital (TMUCIH) is the birthplace of oncology in China. It has developed into one of the largest cancer centers in China.

Nantong WuXi PharmaTech Co., Ltd., established on 2018-04-26, Business scope includes medical technology,Biological Technology,Technology development in the field of detection technology,technology transfer,Technical Consulting and Technical Services(Except for those prohibited by the state for foreign investment);General chemical products(Removal of hazardous chemicals,Monitor Chemicals,firecrackers,civilian explosives,precursor chemicals)Sales,Operate the export business of the company's self-produced products and the import and export business of raw and auxiliary materials required by the company(Commodities that do not involve state trade management,Products involving quota license management,Apply in accordance with relevant national regulations).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Dongdai (Jinan) Intelligent Technology Co., Ltd., established on 2022-04-24, Business scope includes general items:Intelligent control system integration;Artificial intelligence application software development;Internet of things technology research and development;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Emerging energy technology research and development;New material technology research and development;Mechanical equipment research and development;Engineering and Technology Research and Experimental Development;Environmental Protection Monitoring;Professional Design Services;Industrial Design Services;advertisement making;software development;Big data service;internet data service;Technology intermediary service.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Aptose Biosciences is a biopharmaceutical company focused on the discovery, research and development of novel, first-in-class anticancer therapies with high safety profiles. Through its own discovery efforts, as well as partnering activities, Lorus is building a portfolio of promising anticancer drugs ranging from discovery and preclinical to clinical-proof-of concept stage. Lorus seeks suitable partners for subsequent late-stage registration trials and eventual commercialization.